Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

835P - Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Ovarian Cancer

Presenters

Natalie Ngoi

Citation

Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276

Authors

N.Y.L. Ngoi1, A. Lai2, T.Z. Tan3, D.G. Lim4, I.S. Khan4, Y.L. Thian5, B.W. Ang5, K.W. Tham1, P.S. Tong6, J. Ng6, J. Low6, A. Ilancheran6, Y.W. Lim1, S.E. Lim1, D.S. Tan1

Author affiliations

  • 1 Haematology-oncology Department, National University Cancer Institute, Singapore (NCIS), 119228 - Singapore/SG
  • 2 Department Of Medicine, National University Hospital, Singapore/SG
  • 3 N/a, Cancer Science Institute, Singapore, Singapore/SG
  • 4 Department Of Pathology, National University Hospital, Singapore/SG
  • 5 Department Of Diagnostic Imaging, National University Hospital, Singapore/SG
  • 6 Obstetrics And Gynaecology, Division Of Gynaecologic Oncology, National University Hospital, Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 835P

Background

Ovarian clear cell carcinoma (OCCC) is associated with chemotherapy resistance. Limited data are available regarding the efficacy of targeted therapies such as anti-PD1/PDL1 checkpoint inhibitors (CPI) and bevacizumab (Bev) in OCCC. We characterized the molecular features and treatment outcomes of OCCC patients (pts) treated at our institution.

Methods

Retrospective review of medical records and next-generation sequencing (NGS) data, was performed on 157 OCCC pts treated between 2000-2020. Treatment response was assessed by RECIST1.1.

Results

Median age was 54 yrs (range 26-82). 70% pts were Chinese, 12.1% Malay and 7% Indian. At the time of diagnosis, 84(53.5%) had stage I, 17(10.8%) stage II, 42(26.8%) stage III and 13(8.3%) stage IV disease. 127/157(80.9%) pts had optimal debulking. Of 101 stage I-II pts, no difference in relapse-free survival was noted by stage, age, race or chemotherapy on multi-variate analysis. 89/157 pts had advanced/relapsed disease (advOCCC), 22/89(24.7%) pts received Bev, 21/89(23.6%) received CPI and 19/89(21.3%) underwent secondary debulking. An improvement in median progression-free survival (PFS) was noted for advOCCC pts receiving chemotherapy (CTX) + Bev compared to CTX alone in the first-line (17.2 vs 10.5mth, p>0.05), and second-line settings (5.1 vs 3.6mth, p>0.05), respectively. Of 21 pts who received CPI, 17 were evaluable. ORR was 17.6% (3/17) with 3 PR, 3 SD and 11 PD as best response. 2 pts had durable response to pembrolizumab, receiving 29 and 36 cycles of pembrolizumab respectively. 1 durable responder was re-challenged with pembrolizumab plus Bev after PD on pembrolizumab monotherapy, and responded for additional 8mth. NGS on 21 advOCCC tumors revealed common (>20%) mutations in PI3KCA(61.9%), ARID1A(57.1%), TP53(38.1%), KRAS(28.6%) and ERBB3 amplification (23.8%). No mutation in mismatch-repair genes was detected. Median tumor mutational burden was 4 (range 0-11). Mutations in the PI3K/AKT/PTEN/MTOR pathway were associated with worse first-line PFS (Cox regression 1.26, p=0.05).

Conclusions

Encouraging and durable responses were observed following the use of Bev and CPI in advOCCC. Further trials are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

NMRC/CSA-INV-0016/2017.

Disclosure

N.Y.L. Ngoi: Honoraria (self): Johnson & Johnson; Travel/Accommodation/Expenses: AstraZeneca. D.S. Tan: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Honoraria (self): Foundation Medicine; Honoraria (self): Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self): Tessa Therapeutics; Research grant/Funding (institution): Karyopharm Therapeutics; Travel/Accommodation/Expenses: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.